Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2012 Oct:23 Suppl 7:vii33-40. doi: 10.1093/annonc/mds224.

Authors

T Seufferlein¹, J B Bachet, E Van Cutsem, P Rougier; ESMO Guidelines Working Group

Affiliation

¹ Department of Internal Medicine I, University of Ulm, Ulm, Germany.

PMID: 22997452
DOI: 10.1093/annonc/mds224

No abstract available

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Carcinoma, Pancreatic Ductal / diagnosis*
Carcinoma, Pancreatic Ductal / pathology
Carcinoma, Pancreatic Ductal / therapy
Combined Modality Therapy
Deoxycytidine / analogs & derivatives
Deoxycytidine / therapeutic use
Gemcitabine
Humans
Neoplasm Staging
Palliative Care
Pancreatic Neoplasms / diagnosis*
Pancreatic Neoplasms / pathology
Pancreatic Neoplasms / therapy
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Deoxycytidine
Gemcitabine